Siemens Healthineers Stock: AI Imaging Wins FDA Clearances as Barclays Bets on Service Contract Shield

FDA clears six new angiography systems. Stock near 52-week low, but Barclays sees 45% upside via CPI-linked service contracts. Diagnostics challenges persist.

Six new angiography systems from Siemens Healthineers have secured the green light from the US Food and Drug Administration, marking a significant technological push for the medical technology group. The Artis-series devices, outfitted with the Optiq artificial intelligence imaging chain, use machine learning to cut image noise during fluoroscopy and angiography, delivering sharper real-time visuals. On the same front, the company unveiled at the EuroPCR conference in Paris a software combination — Syngo.CT Coronary Cockpit paired with Syngo PCI Connect — that lets physicians pull preoperative CT scans directly into the catheter lab and align imaging with surgical tools on the fly.

Yet for all the innovation on the clinical side, the stock continues to struggle. Shares closed at €34.51 on Friday, barely 3% above the 52-week low of €33.34 hit in mid-May. The equity has shed roughly 22% since the start of the year and now trades nearly 19% below its 200-day moving average.

Against that gloomy price action, Barclays is making a contrarian call. The bank reaffirmed its "overweight" rating and a €50.00 price target, implying upside of about 45% from current levels. The bull case rests on an often-overlooked detail in the company's service contracts: many of them contain price escalation clauses linked to the consumer price index. As labour and material costs rise, Siemens Healthineers can pass those expenses through to customers in near real-time, insulating operating margins from inflation — a structural advantage over competitors that has caught the attention of institutional investors.

The bullish thesis, however, has to contend with persistent headwinds in the diagnostics business. While the imaging segment grew revenues by more than 6% last quarter, the diagnostics unit is buckling under structural challenges in China and elevated inflation. Early in May management trimmed the full-year sales forecast to a range of 4.5% to 5.0%. Adjusted earnings per share slid to €0.53 in the fiscal second quarter. Meanwhile, net debt stood at €13.2 billion at the end of March, equivalent to 3.1 times operating profit, though Moody's maintains an A3 credit rating.

The market's focus now turns to the next catalyst: the third-quarter earnings report expected in July. That release will provide the first real test of whether the price escalation clauses are functioning as an effective margin buffer in practice. On the fundamental side, a durable recovery in the stock will likely require more than product premieres — a measurable stabilisation in diagnostics would be the necessary lever. Management is also set to meet institutional investors in Northern Europe next week to pitch growth targets in imaging and lab diagnostics, keeping the €33.34 support level firmly in view.